Cellegy Cellegesic SPA Clears FDA; NDA Resubmission Planned For Q3 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cellegy’s Special Protocol Assessment agreement with FDA for its anal fissure therapy Cellegesic allows the firm to use pain at three weeks as the primary endpoint for a confirmatory trial.
You may also be interested in...
Cellegy resubmits Cellegesic
Cellegy is requesting a priority review for its June 30 resubmission of Cellegesic (nitrogylcerin ointment, 0.4%). The firm withdrew its NDA for the anal fissure therapy in April 2002 after disagreeing with FDA on statistical analyses in a pain reduction trial. Cellegy had projected resubmission by the third quarter after a special protocol assessment agreement for a confirmatory trial (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 18). Cellegesic would be the first agent approved for anal fissures, which Cellegy says affect over 700,000 in the U.S...
Special Protocol Assessment Requests Up 10%-15% Over FY2002
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.
Special Protocol Assessment Requests Up 10%-15% Over FY2002
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.